APEX1

DNA repair nuclease/redox regulator APEX1 · P27695 · APEX1 on Sugi Atlas →

287,144 patent compounds predicted against APEX1, 214,568 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL14751	0.86	6/20
Theaflavin (SCHEMBL19551)	1.00	5/20
Quercetin (SCHEMBL19723)	1.00	5/20
Isoorientin (SCHEMBL23761)	1.00	5/20
Theaflavin (SCHEMBL19552)	0.81	5/20
Norepinephrine (SCHEMBL2609)	1.00	4/20
L-Norepinephrine (SCHEMBL2610)	1.00	4/20
Epigallocatechin (SCHEMBL19553)	1.00	4/20
Orientin (SCHEMBL25942)	1.00	4/20
Dequalinium (SCHEMBL34043)	1.00	4/20
Quercetin (SCHEMBL22103)	0.97	4/20
Norepinephrine (SCHEMBL2249)	0.96	4/20
Vitexin (SCHEMBL25277)	0.83	4/20
SCHEMBL2250	0.46	4/20
Anazolene (SCHEMBL23594)	0.41	4/20
SCHEMBL33978	0.36	4/20
Daunorubicin (SCHEMBL3041)	1.00	3/20
Idarubicin (SCHEMBL3750)	1.00	3/20
Carubicin (SCHEMBL9552)	1.00	3/20
Myricetin (SCHEMBL19302)	1.00	3/20

Clinical trials — most relevant to APEX1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Satraplatin and Prednisone to Treat Prostate Cancer	PHASE2	COMPLETED
Effect of Arginine- and Glutamine-based Oral Formulations on Salivary Biomarkers and Clinical Severity of Radiation-induced Oral Mucositis in Head and Neck Cancer: A Randomized Controlled Trial	PHASE2	COMPLETED
Olaparib in People With Malignant Mesothelioma	PHASE2	COMPLETED
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)	PHASE2	UNKNOWN
N-Acetylcysteine Protection Against Radiation Induced Cellular Damage	PHASE2	COMPLETED
Evaluation of the Effect of Garcinia in Combination With Chromium on the Clinical Outcomes of Patients With LUTS/BPH	PHASE2	UNKNOWN
A Study of APX3330 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma	PHASE1	RECRUITING
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems	PHASE1	WITHDRAWN
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	nan	UNKNOWN
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE)	nan	ACTIVE_NOT_RECRUITING
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Vascular Senescence and Atherosclerotic Plaque Vulnerability	nan	RECRUITING
Treatment Strategy to Enhance Nrf2 Signaling in Older Adults	nan	COMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN
Pesticide Associated Lymphomas: Expression of Treatment Resistance Genes	nan	COMPLETED
Effectivity Gas Extraction to Prevent Anesthesiologists Waste Gas Exposure of Sevofluorane During Pediatric Induction	nan	NOT_YET_RECRUITING
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility	nan	RECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
Study of the Effect of Innate on the Inflammatory Response to Endotoxin	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a APEX1 binder may also engage these)

Protein	Name	Similarity
A1YFZ3	—	1.000	A1YFZ3 →
A2T6Y4	—	1.000	A2T6Y4 →
P23196	—	1.000	P23196 →
A1YES6	—	1.000	A1YES6 →
A2T7I6	—	1.000	A2T7I6 →
P28352	—	0.998	P28352 →
P43138	—	0.998	P43138 →
A0MTA1	—	0.985	A0MTA1 →
Q5R4Z1	—	0.967	Q5R4Z1 →
O54747	—	0.967	O54747 →
UNG	Uracil-DNA glycosylase	0.967	landscape →
Q3T0G5	—	0.966	Q3T0G5 →
Q4R6C1	—	0.966	Q4R6C1 →
Q7QBJ0	—	0.965	Q7QBJ0 →
A9S0B8	—	0.965	A9S0B8 →
Q9Z2Y8	—	0.965	Q9Z2Y8 →
Q9CR16	—	0.964	Q9CR16 →
Q8BVH9	—	0.964	Q8BVH9 →
Q8CGK3	—	0.964	Q8CGK3 →
P97931	—	0.964	P97931 →
HAGH	Hydroxyacylglutathione hydrolase, mitochondrial	0.964	landscape →
Q3TIU4	—	0.963	Q3TIU4 →
P28339	—	0.963	P28339 →
B4FAT0	—	0.963	B4FAT0 →
Q5XIP6	—	0.963	Q5XIP6 →
Q6AXQ5	—	0.963	Q6AXQ5 →
Q59HJ6	—	0.963	Q59HJ6 →
Q4R5U5	—	0.963	Q4R5U5 →
P52431	—	0.962	P52431 →
Q8TB37	—	0.962	Q8TB37 →